Briacell Therapeutics Corp (BCTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Briacell Therapeutics Corp (BCTX) has a cash flow conversion efficiency ratio of -0.302x as of April 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.08 Million) by net assets ($23.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BCTX equity to assets ratio to measure how much of total assets are equity-financed.
Briacell Therapeutics Corp - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Briacell Therapeutics Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check BCTX operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Briacell Therapeutics Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Briacell Therapeutics Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
3S KOREA Co. Ltd
KQ:060310
|
-0.004x |
|
Broadpeak SA
PA:ALBPK
|
0.056x |
|
Dusk Group Ltd
AU:DSK
|
-0.078x |
|
Stadlauer Malzfabrik Aktiengesellschaft
VI:STM
|
N/A |
|
Ledlink Optics
TWO:5230
|
0.045x |
|
UTI Inc
KQ:179900
|
-0.224x |
|
Grand Ocean Retail Group Ltd
TW:5907
|
0.020x |
|
SANGBO Corp
KQ:027580
|
-0.080x |
Annual Cash Flow Conversion Efficiency for Briacell Therapeutics Corp (2006–2025)
The table below shows the annual cash flow conversion efficiency of Briacell Therapeutics Corp from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see BCTX company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-07-31 | $23.83 Million | $-39.07 Million | -1.639x | -118.54% |
| 2024-07-31 | $-3.73 Million | $-32.97 Million | 8.845x | +39.91% |
| 2023-07-31 | $-5.04 Million | $-31.89 Million | 6.322x | +627.54% |
| 2022-07-31 | $13.25 Million | $-15.87 Million | -1.198x | -319.15% |
| 2021-07-31 | $34.58 Million | $-9.89 Million | -0.286x | -166.16% |
| 2020-07-31 | $-3.60 Million | $-1.55 Million | 0.432x | -94.19% |
| 2019-07-31 | $-688.66K | $-5.12 Million | 7.434x | +241.81% |
| 2018-07-31 | $945.02K | $-4.95 Million | -5.242x | -105.75% |
| 2017-07-31 | $750.23K | $-1.91 Million | -2.548x | -27.07% |
| 2016-07-31 | $787.11K | $-1.58 Million | -2.005x | -95.86% |
| 2015-07-31 | $1.16 Million | $-1.19 Million | -1.024x | -100.29% |
| 2014-07-31 | $-1.13K | $-397.42K | 352.638x | +862188.34% |
| 2013-07-31 | $9.33 Million | $-381.80K | -0.041x | -7.25% |
| 2012-07-31 | $10.03 Million | $-382.74K | -0.038x | +32.46% |
| 2011-07-31 | $11.63 Million | $-656.68K | -0.056x | +74.43% |
| 2010-07-31 | $1.44 Million | $-318.63K | -0.221x | -42.45% |
| 2009-07-31 | $974.50K | $-151.05K | -0.155x | +36.89% |
| 2008-07-31 | $365.17K | $-89.68K | -0.246x | -25.01% |
| 2007-07-31 | $446.71K | $-87.76K | -0.196x | -1492.27% |
| 2006-07-31 | $79.82K | $1.13K | 0.014x | -- |
About Briacell Therapeutics Corp
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that… Read more